AQW051

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced on Monday that it has agreed to settle a dispute over the rights to Fanapt with Novartis AG (ADR) (NYSE: NVS). Under the agreement, Novartis will transfer all rights relating to Fanapt to Vanda Pharmaceuticals in the U.S. and Canada. At the same...